Sellas presents preclinical data on SLS009 CDK9 inhibitor in pancreatic cancer organoid models at AACR conference
Bitget2026/09/25 17:00- Sellas Life Sciences disclosed preclinical pancreatic cancer data for SLS009, a CDK9 inhibitor, from patient-derived organoid studies.
- Results are being presented at the AACR Conference on Pancreatic Cancer, running Sept. 25-28, 2026, in San Diego.
- SLS009 showed stronger single-agent anti-tumor activity than a RAS inhibitor in a resistant, MYC-amplified pancreatic cancer model.
- Combining SLS009 with the RAS inhibitor increased cancer cell death, supporting a potential strategy to address resistance to RAS-directed therapy.
- A separate study pairing SLS009 with BET inhibition produced synergistic activity, consistent with suppressing MYC-driven survival programs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A 6% yield is not "extremely cheap"! Fidelity throws cold water: Long-term inflation and debt risks are key, and US Treasuries may no longer serve as a "safe haven" for the stock market.
In the view of Salman Ahmed, Head of Global Macro and Strategic Asset Allocation at Fidelity International, even if the 10-year US Treasury yield rises to 6%, it would not be considered "extremely cheap."

Japan's exports in October rose 20.5% year-on-year, exceeding expectations; semiconductor equipment exports surged nearly 50%.
Official data released by Japan on Wednesday showed that exports in October rose by 20.5% year-on-year, ending a two-month slowdown.

BUZZ-Ardent Health shares fall after launching secondary public offering
BUZZ - Ardent Health shares fall after launching secondary public offering